|
|
|
|
SPOT ON media and LIVESTRONG(R) Launch LIVESTRONG Quarterly
NEW YORK, Feb.9 /PRNewswire/ -- LIVESTRONG Quarterly is a new online, print and print-on-demand publication from LIVESTRONG. The magazine features profiles of survivors and supporters in the fight against cancer; resources and information about cancer...
|
|
|
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on February 16, 2010
10.5699 0.3699 3.63% Enter Symbols: Sponsored by: Conference Call and Webcast to Follow ROCKVILLE, Md., Feb.9 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and...
|
|
|
Reproductive Partners Announces The Success Prime IVF Program
Reproductive Partners Announces The LOS ANGELES, Feb.9 /PRNewswire/ -- Reproductive Partners Medical Group, Inc. announces the launch of the , an IVF money back guarantee for best-case patients.'The is really very simple,' says Dr. Arthur Wisot of...
|
|
|
Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
Related Quotes Chattem Incorporated 93.32 0.10 0.11% Sanofi Aventis 35.91 0.40 1.13% Enter Symbols: Sponsored by: //var ord = Math.random() * 10000000000000000; write('//var ord = Math.random() * 10000000000000000; write(' PARIS, Feb.9 /PRNewswire-FirstCall/...
|
|
|
Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
ABBOTT PARK, Ill., Feb.8 /PRNewswire-FirstCall/ -- A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the United States. Abbott's ARCHITECT HE4 assay uses a simple blood test to...
|
|
|
Westaim announces completion of amalgamation with NUCRYST Pharmaceuticals Corp.
Related Quotes Westaim Corporation 0.59 UNCH 0.0% Westaim Corporation 0.59 UNCH 0.0% Enter Symbols: Sponsored by: //var ord = Math.random() * 10000000000000000; write('//var ord = Math.random() * 10000000000000000; write(' TORONTO, Feb.8 /CNW/ - The Westaim...
|
|
|
Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions
Style Definitions span.prnews_span span.prnews_wider a.prnews_a li.prnews_li p.prnews_p ST.LOUIS, Feb. 8 /PRNewswire-FirstCall/ -- Cost reductions offset a recession-driven sales decline to move Allied Healthcare Products (Nasdaq: ) narrowly into...
|
|
|
US FDA Approves New Indication for CRESTOR(R) (rosuvastatin calcium)
WILMINGTON, Del., Feb.8 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved CRESTOR (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction (heart attack) and...
|
|
|
RegenceRx Leads the Industry With Introduction of Medication Cost Integration
PORTLAND, Ore., Feb.8 /PRNewswire/ -- Rapid developments in the pharmaceutical industry have led to a steady increase in the use and cost of 'specialty' medications to treat chronic conditions such as arthritis and psoriasis. This has led to some...
|
|
|
Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Pat
THOUSAND OAKS, Calif., Feb.8 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced...
|
